Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III

Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
arcticnovartis

Annonce événementielle au sens de l’art. 53 RC

Exercice complet (activités poursuivies2)

/by
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts

Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Full year (continuing operations2)

/by
In Colombia, a researcher works against a devastating disease

In Colombia, a researcher works against a devastating disease
tavasat1

/by
Going upstream to improve heart health in Philadelphia

Going upstream to improve heart health in Philadelphia
mihai_novartis

/by
A cancer patient gets a new lease on life

A cancer patient gets a new lease on life
tavasat1

/by
A cancer patient gets a new lease on life

A cancer patient gets a new lease on life
tavasat1

/by
Empowering the next generation of healthcare leaders

Empowering the next generation of healthcare leaders
attila_novartis

/by
Empowering the next generation of healthcare leaders

Empowering the next generation of healthcare leaders
attila_novartis

/by
Giving voice to people with a misunderstood disease

Giving voice to people with a misunderstood disease
mihai_novartis

/by
Giving voice to people with a misunderstood disease

Giving voice to people with a misunderstood disease
mihai_novartis

/by